{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,7]],"date-time":"2026-03-07T13:29:26Z","timestamp":1772890166878,"version":"3.50.1"},"reference-count":20,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2018,9,1]],"date-time":"2018-09-01T00:00:00Z","timestamp":1535760000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","lipidjournal.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Clinical Lipidology"],"published-print":{"date-parts":[[2018,9]]},"DOI":"10.1016\/j.jacl.2018.05.017","type":"journal-article","created":{"date-parts":[[2018,6,1]],"date-time":"2018-06-01T09:48:08Z","timestamp":1527846488000},"page":"1141-1145","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":9,"title":["Case reports of proprotein convertase subtilisin\/kexin type 9 (PCSK9) inhibition nonresponse"],"prefix":"10.1016","volume":"12","author":[{"given":"Anum","family":"Saeed","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Salim S.","family":"Virani","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Peter H.","family":"Jones","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christie M.","family":"Ballantyne","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vijay","family":"Nambi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.jacl.2018.05.017_bib1","doi-asserted-by":"crossref","first-page":"394","DOI":"10.1194\/jlr.M700437-JLR200","article-title":"Atorvastatin increases human serum levels of proprotein convertase subtilisin\/kexin type 9","volume":"49","author":"Careskey","year":"2008","journal-title":"J Lipid Res"},{"key":"10.1016\/j.jacl.2018.05.017_bib2","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1007\/s11883-013-0310-3","article-title":"Potential of proprotein convertase subtilisin\/kexin type 9 based therapeutics","volume":"15","author":"Stein","year":"2013","journal-title":"Curr Atheroscler Rep"},{"key":"10.1016\/j.jacl.2018.05.017_bib3","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1016\/j.ahj.2015.11.015","article-title":"Rationale and design of the Further cardiovascular OUtcomes Research with PCSK9 Inhibition in subjects with Elevated Risk trial","volume":"173","author":"Sabatine","year":"2016","journal-title":"Am Heart J"},{"key":"10.1016\/j.jacl.2018.05.017_bib4","doi-asserted-by":"crossref","first-page":"1713","DOI":"10.1056\/NEJMoa1615664","article-title":"Evolocumab and clinical outcomes in patients with cardiovascular disease","volume":"376","author":"Sabatine","year":"2017","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jacl.2018.05.017_bib5","article-title":"Pro-protein subtilisin kexin-9 (PCSK9) inhibition in practice: lipid clinic experience in 2 contrasting UK centres","volume":"71","author":"Monika","year":"2017","journal-title":"Int J Clin Pract"},{"key":"10.1016\/j.jacl.2018.05.017_bib6","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1586\/14779072.2015.1030395","article-title":"Evolocumab (AMG 145) for primary hypercholesterolemia","volume":"13","author":"Langslet","year":"2015","journal-title":"Expert Rev Cardiovasc Ther"},{"key":"10.1016\/j.jacl.2018.05.017_bib7","doi-asserted-by":"crossref","first-page":"1022","DOI":"10.1161\/CIRCRESAHA.114.301621","article-title":"PCSK9","volume":"114","author":"Seidah","year":"2014","journal-title":"Circ Res"},{"key":"10.1016\/j.jacl.2018.05.017_bib8","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1038\/ncpcardio0836","article-title":"Mechanisms of disease: genetic causes of familial hypercholesterolemia","volume":"4","author":"Soutar","year":"2007","journal-title":"Nat Clin Pract Cardiovasc Med"},{"key":"10.1016\/j.jacl.2018.05.017_bib9","doi-asserted-by":"crossref","first-page":"841","DOI":"10.1016\/S0140-6736(02)07955-2","article-title":"Autosomal recessive hypercholesterolaemia in Sardinia, Italy, and mutations in ARH: a clinical and molecular genetic analysis","volume":"359","author":"Arca","year":"2002","journal-title":"Lancet"},{"key":"10.1016\/j.jacl.2018.05.017_bib10","doi-asserted-by":"crossref","first-page":"1795","DOI":"10.1172\/JCI200318925","article-title":"Monogenic hypercholesterolemia: new insights in pathogenesis and treatment","volume":"111","author":"Rader","year":"2003","journal-title":"J Clin Invest"},{"key":"10.1016\/j.jacl.2018.05.017_bib11","doi-asserted-by":"crossref","first-page":"1394","DOI":"10.1126\/science.1060458","article-title":"Autosomal recessive hypercholesterolemia caused by mutations in a putative LDL receptor adaptor protein","volume":"292","author":"Garcia","year":"2001","journal-title":"Science"},{"key":"10.1016\/j.jacl.2018.05.017_bib12","doi-asserted-by":"crossref","unstructured":"Raal FJ, Honarpour N, Blom DJ et\u00a0al. Inhibition of PCSK9 with evolocumab in homozygous familial hypercholesterolaemia (TESLA Part B): a randomised, double-blind, placebo-controlled trial. Lancet;385:341\u2013350.","DOI":"10.1016\/S0140-6736(14)61374-X"},{"key":"10.1016\/j.jacl.2018.05.017_bib13","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1016\/j.jacl.2016.10.002","article-title":"A case of autosomal recessive hypercholesterolemia responsive to proprotein convertase subtilisin\/kexin 9 inhibition","volume":"11","author":"Fahy","year":"2017","journal-title":"J Clin Lipidol"},{"key":"10.1016\/j.jacl.2018.05.017_bib14","doi-asserted-by":"crossref","first-page":"1647","DOI":"10.1161\/ATVBAHA.116.307493","article-title":"Proprotein Convertase Subtilisin Kexin Type 9 Inhibition for Autosomal Recessive Hypercholesterolemia-Brief Report","volume":"36","author":"Thedrez","year":"2016","journal-title":"Arterioscleros Thromb Vasc Biol"},{"key":"10.1016\/j.jacl.2018.05.017_bib15","doi-asserted-by":"crossref","first-page":"4235","DOI":"10.1242\/jcs.03217","article-title":"The adaptor protein Dab2 sorts LDL receptors into coated pits independently of AP-2 and ARH","volume":"119","author":"Maurer","year":"2006","journal-title":"J Cel Sci"},{"key":"10.1016\/j.jacl.2018.05.017_bib16","doi-asserted-by":"crossref","first-page":"181","DOI":"10.2215\/CJN.04680513","article-title":"Principles of separation: indications and therapeutic targets for plasma exchange","volume":"9","author":"Williams","year":"2014","journal-title":"Clin J Am Soc Nephrol"},{"key":"10.1016\/j.jacl.2018.05.017_bib17","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1124\/jpet.114.221242","article-title":"Anti-PCSK9 Antibody Pharmacokinetics and Low-Density Lipoprotein-Cholesterol Pharmacodynamics in Nonhuman Primates Are Antigen Affinity\u2013Dependent and Exhibit Limited Sensitivity to Neonatal Fc Receptor\u2013Binding Enhancement","volume":"353","author":"Henne","year":"2015","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1016\/j.jacl.2018.05.017_bib18","doi-asserted-by":"crossref","first-page":"1457","DOI":"10.1056\/NEJM198006263022607","article-title":"Plasma-exchange therapy of homozygous familial hypercholesterolemia","volume":"302","author":"King","year":"1980","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jacl.2018.05.017_bib19","doi-asserted-by":"crossref","first-page":"1573","DOI":"10.1074\/jbc.M116.769430","article-title":"The Proprotein Convertase Subtilisin\/Kexin Type 9-resistant R410S Low Density Lipoprotein Receptor Mutation: A NOVEL MECHANISM CAUSING FAMILIAL HYPERCHOLESTEROLEMIA","volume":"292","author":"Susan-Resiga","year":"2017","journal-title":"J Biol Chem"},{"key":"10.1016\/j.jacl.2018.05.017_bib20","doi-asserted-by":"crossref","first-page":"376","DOI":"10.7326\/M17-2485","article-title":"Diagnosing resistance to a proprotein convertase subtilisin\/kexin type 9 inhibitor","volume":"168","author":"Shapiro","year":"2018","journal-title":"Ann Intern Med"}],"container-title":["Journal of Clinical Lipidology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1933287418302460?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1933287418302460?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,10,18]],"date-time":"2019-10-18T23:49:51Z","timestamp":1571442591000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1933287418302460"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,9]]},"references-count":20,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2018,9]]}},"alternative-id":["S1933287418302460"],"URL":"https:\/\/doi.org\/10.1016\/j.jacl.2018.05.017","relation":{},"ISSN":["1933-2874"],"issn-type":[{"value":"1933-2874","type":"print"}],"subject":[],"published":{"date-parts":[[2018,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Case reports of proprotein convertase subtilisin\/kexin type 9 (PCSK9) inhibition nonresponse","name":"articletitle","label":"Article Title"},{"value":"Journal of Clinical Lipidology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jacl.2018.05.017","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Published by Elsevier Inc. on behalf of National Lipid Association.","name":"copyright","label":"Copyright"}]}}